Icon, Theranostics Yokohama partnership – Expanding international access to Theranostics

A bridge between Japan and Australia

While interest in theranostics is growing in Japan, access to treatment is limited.

Through this collaboration, Icon and Theranostics Yokohama work closely to identify suitable patients in Japan, guide them through the referral process, and coordinate care with the experienced Theranostics team at Icon Cancer Centre North Lakes, in Brisbane’s northern suburbs.

What is theranostics?

Theranostics is a growing area of medicine that combines advanced diagnostic imaging with highly targeted treatment.

It identifies a person’s unique cancer cells and delivers personalised targeted therapy to the cancer and aims to slow the growth and spread of cancer, relieve symptoms and long-term side effects, and maintain or improve quality of life.

Theranostics may be considered for people with advanced cancer, particularly prostate and neuroendocrine cancer when standard treatment options are unsuitable or no longer effective and symptoms are affecting quality of life.

A shared vision for patient-centred care

Icon’s Clinical Director, Molecular Imaging and Nuclear Oncology (Asia Pacific), Dr Nat Lenzo has worked with Theranostics Yokohama for several years and is excited to continue fostering the partnership.

“Together we’re providing a clear and compassionate pathway for Japanese patients to receive leading theranostics in Australia,” said Dr Lenzo.

“Icon is continuing to invest and build out our precision medicine offering and ensure more people, no matter where they live, can have access to the care they need.”

Yokohama Theranostics Urologist, Dr Kenta Miki echoes this sentiment.

“We’ve been referring our patients to Dr Lenzo and the team at Icon North Lakes for over a year with patients providing exceptional feedback of the centre and their treatment,” said Dr Kenta Miki.

“We look forward to continuing to grow our partnership with Icon and ensure more Japanese people can come and receive their treatment in Australia as we continue to advocate for greater access to care locally.”